Leaflet DAPLAX 1g powder infusion solution
Indicated for: cancer
Route of administration: infusion
Substance: gemcitabine (antimetabolite antineoplastic)
ATC: L01BC05 (Antineoplastic and immunomodulating agents | Antimetabolites | Pyrimidine analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Gemcitabine is a chemotherapy medication used to treat various types of cancer, including lung, pancreatic, breast, and bladder cancer. It is an antimetabolite that interferes with DNA synthesis in cancer cells.
This medication is administered intravenously, usually in cycles, according to a schedule set by the doctor. Gemcitabine helps slow the growth and spread of cancer cells.
Common side effects include nausea, vomiting, fatigue, low blood cell counts, and hair loss. In rare cases, severe reactions such as liver or lung function impairment may occur.
It is essential to follow your doctor's instructions and undergo regular tests to monitor the treatment's effects and manage potential side effects.
General data about DAPLAX 1g
- Substance: gemcitabine
- Date of last drug list: 01-03-2022
- Commercial code: W56150001
- Concentration: 1g
- Pharmaceutical form: powder infusion solution
- Quantity: 1
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for gemcitabine
Concentrations available for gemcitabine
- 1000mg
- 100mg/ml
- 10mg/ml
- 1g
- 2000mg
- 200mg
- 38mg/ml
- 40mg/ml